It is well accepted that MSCs exert therapeutic effects on ischemic diseases by directly producing or stimulating endogenous factors, such as vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and stromal-derived factor-1 (SDF-1) [62,63]. The gene discussed is HGF; the disease is ischemic disease.